Pharma is creating new solutions for a changing marketplace

Companies’ operations must be built upon flexibility, responsiveness, and reliability to meet dynamic business and consumer demands. With a still-sluggish economy and the unknown impact of healthcare reform, companies must respond with new strategies, new business models, and new capabilities. The difference between the industry’s winners and losers may ultimately come down to the basics of operating performance.

Learn about PwC's experience in the Global Health Supply Chain
Learn more.
Quality-based inspections:
A paradigm shift for the regulators and the pharma industry
Learn more.
Knowledge Management: Unlocking
Value in Pharma Life Sciences
Learn more.
1 2 3

Evolving market realities require new operational frameworks

Increasing regulatory scrutiny and expiring patents are contributing to the growing costs of developing new drugs and medical products. Many companies have put their R&D budgets under a microscope or are experimenting with new R&D structures. With less robust product pipelines and the need explore increasingly customized therapies, today’s companies are also looking for improvement in their supply chain with the twin goals of delivering more flexible and responsive operations.

In this new environment, the traditional sales and marketing model of driving revenue with an ever larger sales force is no longer sustainable. Businesses will need to evolve to become more efficient and deliver differentiated messages tailored to the specific needs of diverse customer segments, including patients, insurers, government, and physicians.

A new lens on clinical trials

To speed up clinical trials and reduce costs, the industry is poised to take advantage of alternative approaches.

Learn more.

Supply chain security

Supply chain security

Recently enacted Drug Quality and Security Act establishes a national track and trace program targeting counterfeit medicines.

Learn more.